Evaluation of Adverse Events, Pharmacokinetics, and Disease Activity of Oral ABBV-101 in Adult Patients with Select B-Cell Malignancies

The primary objective of this study is to evaluate the **adverse events** and changes in disease activity associated with the administration of oral ABBV-101 in adult participants diagnosed with select **B-Cell malignancies**. This is clinically relevant as it aims to assess the safety profile and therapeutic impact of ABBV-101, which could inform treatment decisions and improve patient outcomes in this population.

The clinical trial involves a total of **188 participants** diagnosed with select **B-Cell malignancies**. The study population includes both male and female subjects, encompassing an age range that includes both adults and older adults. Participants were selected based on specific criteria, although the principal inclusion criteria are not provided. The trial population includes individuals from a vulnerable population, indicating a need for careful ethical considerations. Lifestyle factors such as diet, physical activity, and habits are not specified in the available data. The selection process and any additional relevant criteria for participation are not detailed by the sponsor.

The clinical trial is designed to evaluate the **adverse events**, changes in disease activity, and pharmacokinetics of oral ABBV-101 in adult participants with select **B-cell malignancies**. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research aimed at assessing the safety and dosage of a new treatment. The trial will employ a randomized, double-blind, controlled design to ensure unbiased results and maintain the integrity of the data collected. The estimated duration of the trial spans from the recruitment start date on June 30, 2024, to the anticipated end date on April 11, 2029.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment of the participant's medical history, current health status, and specific diagnostic tests related to B-cell malignancies. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor the participant's response to the treatment, assess any adverse events, and collect pharmacokinetic data. The frequency and number of follow-up visits will be determined by the study protocol, ensuring consistent monitoring throughout the trial period.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, a final evaluation will be conducted to assess the overall impact of the treatment and document any long-term effects. The expected length of participant involvement will vary depending on individual response and the specific requirements of the study protocol. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, withdrawal of consent by the participant, or any other protocol-defined criteria that necessitate discontinuation for safety or ethical reasons.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided dataset. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on June 30, 2024, with an estimated completion date of April 11, 2029. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize a range of parameters such as biomarker levels, symptom improvement scores, or other relevant clinical measures to evaluate efficacy. These parameters are typically measured at predefined intervals throughout the trial to monitor changes over time. The data collected will be analyzed using appropriate statistical methods to determine the efficacy of the investigational product. The trial will adhere to rigorous standards to ensure the reliability and validity of the efficacy assessments.